PT - JOURNAL ARTICLE AU - Daniela Huzly AU - Marcus Panning AU - Franziska Smely AU - Martin Enders AU - Johanna Komp AU - Daniel Steinmann TI - Validation and performance evaluation of a novel interferon-γ release assay for the detection of SARS-CoV-2 specific T-cell response AID - 10.1101/2021.07.17.21260316 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.17.21260316 4099 - http://medrxiv.org/content/early/2021/07/22/2021.07.17.21260316.short 4100 - http://medrxiv.org/content/early/2021/07/22/2021.07.17.21260316.full AB - Background The reliable detection of the T-cell mediated response to COVID-19 or COVID-19 vaccination is important for individual patient care and for monitoring the immune response e.g. in COVID-19 vaccine trials in a standardized fashion.Methods We used blood samples from health care workers (HCW) with or without history of COVID-19 to define test accuracy of a novel interferon-release assay. Usefulness of qualitative and quantitative results after COVID-19 vaccination was examined in HCW receiving homologous or heterologous vaccination regimens. For a real-life performance evaluation, we analysed interferon-response to complete vaccination in 149 patients receiving immunosuppressive or immune modulating therapies.Results Using a double-cut-off strategy integrating the result of background stimulation the assay had a specificity of 100%. Sensitivity of the IGRA was 83.5 and 100% in HCW after SARS-CoV-2 infection more or less than 6 months ago. Quantitative results showed significant differences between first and second vaccine dose, but no difference between homologous and heterologous vaccination regimen. The majority of immunocompromised patients showed no immune response or isolated T-cell or antibody response to complete vaccination.Conclusions The novel IGRA proved to be a highly specific and sensitive tool to detect the SARS-CoV-2 specific T-cell response to COVID-19 as well as COVID-19 vaccination. In perspective, it may serve as a standardized tool in COVID-19 vaccine trials and in clinical care of immunosuppressed patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics The study was approved by the ethics committee of Albert-Ludwigs University Freiburg, head Prof. Korinthenberg, (#20-1271, Nov 24, 2020 and #20-1271_1 amendment for vaccinated HCW, Jan 18, 2021). Written informed consent was obtained from all participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data can be found in the supplementary file.